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ABSTRACT
Introduction: Malignant pleural mesothelioma (MPM) is an
aggressive malignancy linked to asbestos exposure. On a
genomic level, MPM is characterized by frequent chromo-
somal deletions of tumor suppressors, including micro-
RNAs. MiR-137 plays a tumor suppressor role in other
cancers, so the aim of this study was to characterize it and
its target Y-box binding protein 1 (YBX1) in MPM.
Methods: Expression, methylation, and copy number status
of miR-137 and its host gene MIR137HG were assessed by
polymerase chain reaction. Luciferase reporter assays
conﬁrmed a direct interaction between miR-137 and Y-box
binding protein 1 gene (YBX1). Cells were transfected with a
miR-137 inhibitor, miR-137 mimic, and/or YBX1 small
interfering RNA, and growth, colony formation, migration
and invasion assays were conducted.
Results: MiR-137 expression varied among MPM cell lines
and tissue specimens, which was associated with copy
number variation and promoter hypermethylation. High
miR-137 expression was linked to poor patient survival. The
miR-137 inhibitor did not affect target levels or growth, but
interestingly, it increased miR-137 levels by means of mimic
transfection suppressed growth, migration, and invasion,
which was linked to direct YBX1 downregulation. YBX1 was
overexpressed in MPM cell lines and inversely correlated
withmiR-137. RNA interference–mediated YBX1 knockdown
signiﬁcantly reduced cell growth, migration, and invasion.
Conclusions: MiR-137 can exhibit a tumor-suppressive
function in MPM by targeting YBX1. YBX1 knockdown
signiﬁcantly reduces tumor growth, migration, and invasion
of MPM cells. Therefore, YBX1 represents a potential target
for novel MPM treatment strategies.
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
Malignant pleural mesothelioma (MPM) is an
aggressive malignancy arising from the mesothelial lin-
ing of the pleural cavity after asbestos exposure. Present
therapeutic options for MPM are limited—the current
standard combination of cisplatin and pemetrexed is
largely palliative and provides a modest median survival
of 12.1 months.1,2 Despite resounding epidemiological
evidence associating asbestos consumption and MPM
incidence, nine of the 10 most populous countries in the
world have yet to implement a complete asbestos ban.3,4
Factoring in the extended latency period between
asbestos exposure and MPM development (30–50
years), global MPM incidence is expected to rise within
the next decade.3 Therefore, better characterization of
MPM biology to aid in the development of new thera-
peutic strategies is essential.
Next-generation sequencing data has conﬁrmed an
association between MPM development and the loss of
three key tumor suppressors.5 Downregulation of p16
(encoded by cyclin-dependent kinase inhibitor 2A gene
[CDKN2A]) is linked to copy number loss of region 9p21-
22.6 p16 acts on cyclin-dependent kinases such as cyclin-
dependent kinase 4, and homozygous deletion of CDKN2A
has been reported in 65% to 70% of MPM samples.6,7 The
deubiquitinating hydrolase BRCA1 associated protein 1
(BAP1) functions in DNA damage response and cell cycle
regulation,8 and the BRCA1 associated protein 1 gene
(BAP1 gene) located on chromosome 3p21.1 is deleted in
40% of MPM cases.9 Finally, merlin, a cytoskeletal protein
encoded by neuroﬁbromin 2 gene (NF2) at 22q12.2, me-
diates contact inhibition in normal cells and is an up-
stream suppressor of the Hippo pathway.10 It is deleted in
more than 40% MPM cases, with dysregulation of the
Hippo pathway occurring in 80%.11
In addition to these regions, deletion of 1p21-22 has
been reported in up to 70% of MPM cases,9,12 but to our
knowledge there is little information regarding the impli-
cations of 1p21-22 deletion forMPMbiology. Interestingly,
the deletion of this regionwas signiﬁcantly associatedwith
9p21-22 locus loss in MPM,13 which (in addition to
CDKN2A) is also home to themicroRNA (miRNA)miR-31, a
tumor suppressor that is also frequently lost through ho-
mozygous deletion of this region.14 miRNAs are small,
noncoding RNAs that are fundamentally involved in the
regulation of almost all biological processes.15 Many are
located at fragile sites and are often silenced in cancer
through deletion or promoter hypermethylation.15,16 The
dysregulation of numerous miRNAs has been linked to the
development and progression of human cancer, and
recently, miRNA-based therapeutics have shown promise
in tumors such as MPM.17,18
As the consequences of 1p21-22 locus deletion in
MPM biology are poorly understood, we investigated the
role of miR-137 in MPM because its host gene is located
at 1p21.3. MiR-137 has demonstrated tumor-
suppressive activity in colorectal cancer (CRC) and
glioblastoma multiforme,19,20 although its role in MPM is
unknown. Here, we characterize the expression and
functions of miR-137 in MPM and explore the role of one
of its targets, Y-box binding protein-1 (YBX1), in the
context of MPM biology.
Materials and Methods
Cell Culture
Cells were maintained in Roswell Park Memorial
Institute medium supplemented with 10% heat-
inactivated fetal bovine serum (both Thermo Fisher
Scientiﬁc, Waltham, MA) in a humidiﬁed atmosphere
(5% CO2 at 37 C). The cell lines and their source and
histological subtype are listed in Supplementary Table 1.
Cells were routinely monitored for mycoplasma, and
their identity was conﬁrmed by short tandem repeat
proﬁling (Australian Genome Research Facility).
Patient Samples
We obtained formalin-ﬁxed, parafﬁn-embedded
(FFPE) tissue samples from two cohorts (n ¼ 115) of
patients who underwent extrapleural pneumonectomy
from 1994 to 2009 at Royal Prince Alfred and Strathﬁeld
Private Hospitals, Sydney, Australia, or pleurectomy
and/or decortication (P/D) between 1991 and 2009 at
Royal Prince Alfred Hospital.21,22 FFPE pleural and
pericardium control samples (n ¼ 23) were obtained
through nonmalignant cardiovascular surgery. A third
series, consisting of fresh frozen (F/F) samples (n ¼ 12),
was obtained from patients who underwent extrapleural
pneumonectomy, pleurectomy and/or decortication, or
video-assisted thoracoscopic surgery from 2009 to 2012
at Royal Prince Alfred and Strathﬁeld Private Hospitals,
Sydney, Australia. The use of all samples was approved
by the Human Research Ethics Committee at Concord
Repatriation General Hospital, Sydney, Australia.
Transfection with MicroRNA Inhibitors, Mimics,
and siRNAs
miRCURY miR-137 locked nucleic acid (LNA) inhibitor
and miRCURY LNA inhibitor negative controls were pur-
chased from Exiqon (Vedbæk, Denmark) (Supplementary
Table 2). MiR-137 mimic, Y-box binding protein 1 gene
(YBX1)-speciﬁc small interfering RNA (siRNA), and vali-
dated negative control mimic and siRNA were purchased
from Shanghai GenePharma (Shanghai, China) (see
Supplementary Table 2). Cells were reverse-transfected
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using 0.1% Lipofectamine RNAiMAX (Thermo Fisher Sci-
entiﬁc) as per the manufacturer’s protocol.
Copy Number Variation
Genomic DNA was extracted using the QIAamp DNA
mini kit (Qiagen, Hilden, Germany). Primer sequences
and a schematic representation of their location are in
Supplementary Table 3 and Supplementary Fig. 1. Copy
number variation (CNV) of the miR-137 host gene
(MIR137HG) region was assessed by droplet digital po-
lymerase chain reaction (PCR) using Evagreen (Bio-Rad,
Hercules, CA). Ribonuclease P/MRP subunit 30 gene
(RPP30) was used as a reference gene and HindIII was
used to digest DNA (New England Biolabs, Ipswich, MA).
Droplets were generated with a QX200 droplet gener-
ator and read on a QX200 droplet reader (both Bio-Rad)
per the manufacturer’s guidelines.
MSP and Genomic DNA Extraction
Methylated- and unmethylated-speciﬁc primers
(Supplementary Table 4) were designed within CpG
islands surrounding the MIR137HG gene by using the
MethPrimer methylation mapping program,23 as per
standard methylation-speciﬁc polymerase chain reaction
(MSP) design guidelines. Genomic DNA was extracted.
Buffy coat DNA and EpiTech Control unmethylated DNA
(Qiagen) served as methylation negative controls.
HCT116 DNA served as a methylation positive control, as
MIR137HG is methylated in this cell line.19 Bisulphite
conversion was conducted with an EZ DNA methylation
kit (Zymo Research, Irvine, CA). End point PCR (Ampli-
Taq GOLD DNA kit, Thermo Fisher Scientiﬁc) and
quantitative MSP (qMSP) using HCT116 as a methylation
calibrator was conducted with the aforementioned
primers and the KAPA SYBR FAST kit (KAPA Biosystems,
Wilmington, MA) per the manufacturer’s guidelines (see
Supplementary Table 4). Methylation-speciﬁc primers
for a region of the actin beta gene (ACTB) which no CpG
sites were found were used as a reference gene for qMSP
(see Supplementary Table 4). End point PCR products
were run on an agarose gel and visualized on a Kodak
Gel Logic 2200 imaging system (Eastman Kodak Com-
pany, Rochester, NY).
Assessing pri-miR-137 Expression in Mouse MPM
Xenograft Models
Xenografts were grown by injecting H226 and MSTO
cells subcutaneously into BALB/c nude mice. The mice
were killed and the tumors were surgically removed.
Samples were snap-frozen and homogenized, and RNA
was isolated by using TRIzol. The use of animals was
approved by the Sydney South West Area Health Service
(2011-007). The primers and probes for human or
mouse pri-miR-137 are in Supplementary Table 5.
Luciferase Reporter Assay
A fragment of YBX1 30 untranslated region containing
the miR-137 binding site was cloned from cDNA from
SPC212 cells and ampliﬁed using AmpliTaq Gold 360
(Promega, Madison, WI) with speciﬁc primers
(Supplementary Table 6). PCR amplicons were cloned
into the TOPO TA vector (Thermo Fisher Scientiﬁc) and
subcloned into the pSiCheck2 plasmid (Promega). The
sequence was conﬁrmed by Sanger sequencing at the
Ramaciotti Centre (University of New South Wales,
Sydney, Australia). The reporter construct (1 mg), with
miRNA mimic or controls (5 nM) were transfected in 2 
105 cells in six-well plates. A dual luciferase assay
(Promega) was performed per the manufacturer’s pro-
tocol 48 hours after transfection.
Protein Isolation and Western Blot
Cells were transfected with 5 nM miRNA mimic,
siRNAs, or controls. After indicated time points, protein
was isolated in radioimmunoprecipitation assay buffer
(including protease inhibitor cocktail [Roche Diagnostics,
Mannheim, Germany]) and the concentration was
measured by using a Pierce bicinchoninic protein assay
(Thermo Fisher Scientiﬁc). Proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electropho-
resis and blotted onto polyvinylidene ﬂuoride mem-
branes. Immunodetection was performed using a
monoclonal rabbit anti–YBX1 antibody (Abcam, Cam-
bridge, UK; 1:1000). b-actin (Sigma Aldrich, Dorset, UK)
served as a loading control. Densitometry was per-
formed with ImageJ.24
Videomicroscopy
Cells (2  103) were seeded into eight-well chamber
slides (Ibidi, Planegg, Germany). Forty-eight hours after
transfection with 5 nM of either miR-137 mimic, YBX1
siRNA, or controls, cells were treated with 2 mg/mL
mitomycin-C for 2 hours. The next day, cells were
stained with cell tracker (Abcam) for 30 minutes. Videos
were generated using a PALM MicroBeam laser micro-
dissection microscope (Zeiss, Oberkochen, Germany)
with pictures taken every 30 minutes for 25 hours. The
distance migrated by at least 40 single cells was manu-
ally tracked with ImageJ software.
Agarose-Spot Invasion Assay
Cells (1.2  105) were transfected with 5 nM miR-
137 mimic, YBX1 siRNA, or the respective controls. The
next day, cells were treated with 2 mg/mL mitomycin-C
for 2 hours and then replated into 24-well plates pre-
pared with agarose spots consisting of 7.5 mL 2% low-
melting agar containing 0.4% fetal bovine serum
(adapted from Cheng et al. 201425). Images were taken
after 48 hours and quantiﬁed with ImageJ software.
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Figure 1. miR-137 is variably expressed in malignant pleural mesothelioma (MPM) cell lines because of copy number variation
and promoter hypermethylation. (A) Endogenous expression of miR-137 in cell lines compared with RNA U6, small nuclear 6,
pseudogene, determined by reverse-transcriptase quantitative polymerase chain reaction (PCR). MeT-5A (white) served as
the control (Co), MPM cell lines are in black (B) Copy number (white, no change; black, loss, and gray, gain) of MIR137 host
gene (MIR137HG) in cell lines normalized to the ribonuclease P protein subunit p30 (RPP30) assessed by digital droplet PCR.
(C) Expression of miR-137 was determined by reverse-transcriptase PCR after treatment with either 5 mM 5-azacitidine (5-Aza
[gray]) or vehicle (Co [black]). (D) Quantitative methylation-speciﬁc PCR of the MIR137HG of cell lines using the actin beta
gene (ACTB) as a reference gene and HCT116 as the methylation calibrator. (E) Methylation-speciﬁc PCR products run on a
1.5% (wt/vol) agarose gel. (F) The relationship (signiﬁcant using Spearman’s rank correlation, r ¼ 0.58442, p ¼ 0.00429)
between miR-137 expression and MIR137HG copy number status in MPM cell lines (n ¼ 22), as determined by expression array
and array comparative genomic hybridization, respectively. ***p < 0.001. U, unmethylated primer pair; M, methylated
primer pair.
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Figure 2. Differential expression of miR-137 because of promoter methylation has prognostic signiﬁcance in patients with
malignant pleural mesothelioma (MPM). (A) Levels of miR-137 in MPM (n ¼ 115) and mesothelial (control [Co]) (n ¼ 23)
formalin-ﬁxed parafﬁn-embedded tissue specimens determined by reverse-transcriptase quantitative polymerase chain re-
action (RT-qPCR) using RNA U6, small nuclear 6, pseudogene gene (RNU6B) as a reference gene. Data are expressed as fold
change relative to the mean of healthy Co samples (log2(DDCq)) plus or minus the SE of the mean. (B) Kaplan-Meier curve
showing prognostic signiﬁcance of miR-137 in the cohort of formalin-ﬁxed parafﬁn-embedded samples (signiﬁcant using the
Mantle-Cox test [p ¼ 0.0065]). High- and low-expressing groups were dichotomized by a more than twofold change to the
median of the cohort. (C) Expression of hsa- and mmu-pri-miR-137 in mouse xenografts with human MPM cells, determined by
RT-qPCR using 18S as a reference gene and expressed as 2
ˇ
dCT  106. (D) Expression of miR-137 in the cohort of fresh frozen
(F/F) samples, determined by RT-qPCR using RNU6B as a reference gene. (E) Kaplan-Meier survival curve of the cohort of F/F
samples (signiﬁcant using the Mantle-Cox test [p ¼ 0.0218]). (F) Copy number variation of the cohort of F/F samples (white,
no change; black, loss; and gray, gain) of MIR137 host gene (MIR137HG) in cell lines normalized to the ribonuclease P protein
subunit p30 (RPP30) assessed by digital droplet polymerase chain reaction. (G) Quantitative methylation-speciﬁc polymerase
chain reaction of MIR137HG of the cohort of F/F patient samples using the actin beta gene (ACTB) as a reference gene and
HCT116 as the methylation calibrator. *p < 0.05, **p < 0.01.
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Statistical Analysis
Unless stated otherwise, data are presented as mean
plus or minus SE of the mean. Statistical analysis was
carried out with Prism7.0 software (GraphPad Soft-
ware, La Jolla, CA), Social Science Statistics online cal-
culators (Kirkman, TW. Statistics to use. http://www.
physics.csbsju.edu/stats; date accessed: August 24,
2017), and SPSS software (IBM Corp., Armonk, NY). A
Kolmogorov-Smirnov test was used to determine
whether data were normally distributed. A two-tailed
unpaired t test was used to test for signiﬁcant differ-
ences for normally distributed data. A two-tailed Mann-
Whitney test with a signiﬁcance level of 0.05 was
conducted to test for signiﬁcant differences on data that
were not normally distributed. A one-way analysis of
variance was conducted to analyze the proliferation
assay data. Pearson correlation was used to investigate
correlations of normally distributed data. Spearman’s
rank correlation was used to investigate correlations of
data that were not normally distributed. Patient sur-
vival was tested by using a Mantel-Cox Kaplan Meier
test. All p values less than 0.05 were considered sta-
tistically signiﬁcant.
Details on additional methods including RNA
isolation, quantitative PCR (qPCR), gene expression
arrays, and standard growth and migration assays
are described in the Supplementary Materials and
Methods.
Results
Copy Number Variation and Promoter
Hypermethylation Contribute to Aberrant miR-
137 Expression in MPM
Basal miR-137 expression was determined in a
panel of 11 MPM cell lines and the immortalized
mesothelial cell line MeT-5A by RT-qPCR. MiR-137 was
aberrantly expressed in most cell lines compared with
MeT-5A. Four cell lines (H2052, H28, H226, and
VMC23) expressed notably lower and one (VMC40)
expressed notably higher miR-137 levels (Fig. 1A). To
better understand this variable expression, we deter-
mined the copy number status of the exon encoding
MIR137HG by digital droplet PCR. CNV was evident in
seven of 11 cell lines (Fig. 1B). Although there was no
signiﬁcant correlation, two low-expressing cell lines
(H2052 and VMC23) also exhibited loss of heterozy-
gosity (LOH), and VMC40 and MSTO, which had among
the highest levels of miR-137, displayed copy number
gains.
We suspected that methylation of the MIR137HG
promoter also contributes to the variable expression
observed, so we investigated the effects of the deme-
thylating agent 5-aza-cytidine (5-Aza) on miR-137
expression. 5-Aza upregulated miR-137 in all cell
lines, particularly in the low-expressing subgroup,
which demonstrated marked miR-137 reexpression
(Fig. 1C). To conﬁrm that the response to 5-Aza was
due to methylation of the MIR137HG promoter, we
conducted qMSP. The four low-expressing cell lines
exhibited high miR-137 promoter methylation, whereas
high-expressing cell lines exhibited low promoter
methylation; the exception was MSTO, which also dis-
plays gene ampliﬁcation (Fig. 1D). We then conducted
end point MSP to conﬁrm our qMSP data in the highest-
(VMC40) and lowest- (VMC23) expressing cell lines
(Fig. 1E).
To validate our CNV data, we performed gene
expression arrays and array comparative genomic
hybridization to assess MIR137HG expression and
copy number status in a larger, partially overlapping
set of cell lines (n ¼ 22). In that panel, a similar
variable expression pattern was seen (Supplementary
Fig. 2), and there was signiﬁcant correlation between
miR-137 expression and MIR137HG copy number
status (Spearman’s r ¼ 0.58442, p ¼ 0.00429)
(Fig. 1F).
To see whether the variable miR-137 expression
was also evident in MPM tumor samples, we deter-
mined the expression of miR-137 in 115 MPM tumor
and 23 normal mesothelial FFPE tissue specimens.
Consistent with our results in cell lines, both MPM tu-
mor and normal mesothelial tissue exhibit highly vari-
able miR-137 expression (Fig. 2A). To assess the
potential contribution of stromal cells to miR-137
levels, we measured human and mouse pri-miR-137
expression in mouse xenografts. We found that hsa-
pri-miR-137 expression was overwhelmingly higher
than mmu-pri-miR-137 expression, suggesting that the
observed miR-137 primarily originates from tumor
cells and stromal contribution is limited (Fig. 2B). The
effect of high and low miR-137 levels (deﬁned by more
than a twofold change to the median of the tumor
cohort) on patient survival was analyzed by utilizing a
Kaplan-Meier curve (Fig. 2C). Patients with low miR-
137 expression survived signiﬁcantly longer than pa-
tients with high miR-137 expression (p ¼ 0.0065,
Mantle-Cox test). To validate these ﬁndings and to
analyze CNV and methylation in patient samples, we
determined the expression of miR-137 in a smaller
cohort of F/F samples (n ¼ 12). We found a similar
spread of expression (Fig. 2D) and, when analyzed with
the same parameters as the FFPE cohort, patients with
low miR-137 expression also survived signiﬁcantly
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Figure 3. miR-137 mimic inhibits the proliferation and colony formation ability of malignant pleural mesothelioma (MPM) cell
lines. (A) Growth inhibition assay of MPM cell lines 96 hours after transfection with miR-137 locked nucleic acid (at 20 nM and
40 nM) as well as RRM1 siRNA (1 nM) normalized to two locked nucleic acid controls (Cos) (40 nM). Data are expressed as the
mean plus or minus SE of the mean of three independent experiments performed in triplicate. (B) Growth of MPM cell lines
was followed for 96 hours after transfection of miR-137 or Co mimic at the indicated concentrations. Data are expressed as
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longer than those with high expression (p ¼ 0.0218)
(Fig. 2E). MiR-137 was not associated with age, sex, or
histological subtype in either the cohort of FFPE sam-
ples or the cohort of F/F samples. Clinicopathological
patient characteristics are summarized in
Supplementary Tables 7 and 8. CNV of the MIR137HG
was determined by using the same protocol as in
Figure 1B, and although one sample demonstrated LOH
and two copy number gains, this did not correlate with
expression (Fig. 2F). We conducted qMSP using the
same protocol as in Figure 1D. Of the six samples dis-
playing relatively low miR-137 expression, three dis-
played higher levels of methylation, which was
consistent with our cell line data (Fig. 2G).
miR-137 Suppresses MPM Cell Growth and
Colony Formation
As we showed that high miR-137 expression is
associated with poor patient outcome, we investigated
the effect on growth of inhibiting its expression with a
miR-137 miRCURY LNA inhibitor in eight MPM cell lines.
Inhibitor transfection resulted in a decrease of miR-137
expression (Supplementary Fig. 3), but no signiﬁcant
effect on growth was observed in any cell line over 96
hours (Fig. 3A). As a subgroup of MPM cells lines and
patient samples displayed reduced expression of miR-
137, we also investigated the effect of increasing miR-
137 levels using a miRNA mimic. Mimic transfection
led to increased miR-137 levels (see Supplementary
Fig. 3) as well as signiﬁcant growth inhibition over 96
hours in seven of eight cell lines (Fig. 3B). Generally, cell
lines expressing low or moderate endogenous miR-137
(MM05, Ren, H2452, SPC212) displayed greater growth
inhibition in response to miR-137 mimic, compared with
the higher-expressing cell lines (VMC40, VMC20). MiR-
137 mimic transfection also disrupted colony forma-
tion in ﬁve of eight MPM cell lines (Fig. 3C).
miR-137 Regulates Cell Migration and Invasion
The effect of miR-137 on cell migration was assessed
by live cell videomicroscopy and manual single-cell
tracking. MiR-137 mimic transfection signiﬁcantly
reduced the motility of low (H28, VMC23) or moderate
(SPC212) miR-137–expressing cells compared with
mimic control transfection. VMC40, which expresses
high miR-137 levels, was unaffected (Fig. 4A and B).
Wound healing assays performed on the same cell lines
after transfection with miR-137 or control mimic
conﬁrmed these observations (Fig. 4C). Invasion was
investigated by using agarose-spot assays after mimic
transfection, which signiﬁcantly reduced the invasive
potential of all MPM cells. Again, these effects were more
prominent in cell lines expressing low-to-moderate
levels of miR-137 (SPC212, H28, and VMC23) (Fig. 4D).
miR-137 Targets the Oncoprotein YBX1, Which Is
Highly Expressed in MPM
After transfecting six MPM cell lines with miR-137
mimic and miR-137 LNA inhibitor, we quantiﬁed the
expression of several cancer-associated miR-137 target
genes. AKT/serine threonine kinase 2 gene (AKT2),
cyclin-dependent kinase 6 gene (CDK6), and YBX1 tran-
scripts were unaffected by miR-137 LNA inhibitor
transfection but were signiﬁcantly down-regulated in
response to miR-137 mimics (Fig. 5A). We then focused
on the miR-137/YBX1 interaction, as it was the most
prominently down-regulated target. MiR-137 also down-
regulated YBX1 protein in three of four cell lines; VMC40
(with high miR-137) showed no change in YBX1 levels,
although it has low basal YBX1 expression (Fig. 5B). The
30 untranslated region of YBX1 linked to a luciferase
reporter demonstrated that miR-137 directly binds to
YBX1 (Fig. 5C).
Basal YBX1 protein and YBX1 mRNA levels were
analyzed by Western blot and RT-qPCR in all MPM cell
lines and the mesothelial cell line MeT-5A and were
found to be signiﬁcantly correlated (Pearson’s r ¼
0.6584, p ¼ 0.0276, Supplementary Fig. 4). YBX1 protein
expression showed a signiﬁcant inverse correlation with
basal miR-137 expression (Spearman’s r ¼ –0.64693,
p ¼ 0.03145) (Fig. 5D). Importantly, irrespective of basal
miR-137 expression, YBX1 levels were consistently
higher in MPM cell lines than in the MeT-5A cell line (see
Fig. 5D [red line]), implying an important role of YBX1 in
MPM biology.
YBX1 Knockdown Decreases MPM Cell
Proliferation, Colony Formation, Migration, and
Invasion
To determine whether downregulation of YBX1 con-
tributes to the tumor-suppressing activity of miR-137,
we performed several assays after transfection with
YBX1–speciﬁc siRNA alone and in combination with miR-
137 mimic. RNA interference–mediated YBX1 knock-
down signiﬁcantly decreased YBX1 mRNA and YBX1
protein levels (Supplementary Fig. 5). Proliferation
the mean plus or minus SE of the mean of the percentage of Co-transfected cells at 96 hours and is representative of three
independent experiments performed in triplicate. (C) Representative pictures of the colonies formed after transfection with
miR-137 or Co mimic transfection. The histogram shows quantiﬁcation of crystal violet in colonies formed by cells transfected
with miR-137 (5 nM) normalized to Cos. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. miR-137 inhibits malignant pleural mesothelioma (MPM) cell migration and invasion. (A) Representative pictures of
manually tracked migration of H28 cells transfected with miR-137 or control (Co) mimics (5 nM) over 25 hours using ImageJ
software. Scale bar ¼ 100 mm. (B) Cumulative migrated distance (mm) of single cells transfected with miR-137 or Co mimics (5
nM) in 25 hours assessed by videomicroscopy. (C) Percentage gap closure of miR-137–transfected cells (5 nM) normalized to
Cos after 12 hours in a wound healing assay. (D) Invasion of cells transfected with 5 nM miR-137 relative to respective Cos in
an agar-spot (white line) invasion assay after 48 hours. Dotted lines represent invasion by Co- (black) and miR-137–trans-
fected (blue) cells. Scale bar ¼ 250 mm. **p < 0.01, ***p < 0.001.
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assays showed that VMC40 (with low YBX1 levels) was
only moderately affected, whereas VMC23 and SPC212
(high YBX1 levels) showed a signiﬁcant decrease in cell
growth by YBX1 reduction by siRNA alone and in com-
bination with mimic (Fig. 6A). H28 cells were unaffected
by YBX1 knockdown alone but showed signiﬁcantly
reduced growth in combination with miR-137, indicating
that targets other than YBX1 are important to growth in
this cell line. We also conducted colony formation, in-
vasion, and motility assays. Importantly, YBX1 knock-
down resulted in signiﬁcantly impaired colony formation
with miR-137 mimic or a combination of miR-137 and
YBX1-siRNA (Fig. 6B–D and Supplementary Fig. 6),
conﬁrming that YB1 plays a substantial role in the miR-
137–mediated regulation of the invasive behaviour of
MPM cells.
Discussion
Recent reports have highlighted the important bio-
logical consequences of dysregulated miRNAs in
MPM.14,18,26–28 We have shown that miR-137 belongs to
this list of aberrantly expressed miRNAs and that its
target, YBX1, is important in the malignant characteris-
tics of MPM. The considerable variation of miR-137
expression in cell lines and tumor samples suggests
that it plays a complex role in MPM biology. LOH in the
chromosomal region 1p21-22 (which includes
MIR137HG) has been observed in MPM, although its
consequence is largely unreported.12 Abnormalities of
1p21-22 are linked to reduced patient survival in other
tumor types, including multiple myeloma and plasma
cell leukemia.29,30 In the present study, we have shown
that CNV of MIR137HG correlated with mature
A B
C D
Figure 5. miR-137 suppresses oncoprotein YBX1, which is overexpressed in malignant pleural mesothelioma (MPM), by direct
interaction with its mRNA. (A) Expression of three miR-137 target genes 48 hours after transfection with 5 nM miR-137
normaliZed to control (Co) mimics and 20 nM miR-137 locked nucleic acid inhibitor normalized to both negative inhibitor
Cos in six MPM cell lines, determined by reverse-transcriptase quantitative polymerase chain reaction. 18S was used as a
reference gene. (B) Immunoblot of YBX1 and b-actin (which served as loading Co) 72 hours after transfection with 5 nM of
miR-137 (þ) or Co (–) mimics. (C) Normalized percentage of luciferase activity (renilla-to-ﬁreﬂy ratio [RL/FL]) 48 hours after
transfection with microRNA or Co mimics (5 nM) in two MPM cells. (D) Results of densitometry analysis of immunoblots after
normalization to b-actin (y axis) and miR-137 expression levels (from reverse-transcriptase quantitative polymerase chain
reaction [x axis]). Dotted lines indicate the levels of YBX1 and miR-137 in MeT-5A cells. A Spearman’s rank correlation showed
that there was a signiﬁcant negative correlation (r ¼ –0.64693, p ¼ 0.03145).
February 2018 miR-137 and Its Target YBX1 in MPM 267
AC
D
B
268 Johnson et al Journal of Thoracic Oncology Vol. 13 No. 2
microRNA expression in cell lines. In contrast, it was not
related to expression in our cohort of F/F patient sam-
ples, although it should be noted that this series is small
(n ¼ 12). Taking this into account, we cannot rule out a
role for CNV in the dysregulation of miR-137 in MPM,
and further inquiry with a larger series of patient sam-
ples must be conducted to validate our ﬁndings.
As CNV alone did not conclusively explain the vari-
able expression we observed, we investigated the role of
promoter methylation in miR-137 variance in cell lines
and patient samples. We have shown that 5-Aza treat-
ment results in reexpression of miR-137 and have
quantitatively demonstrated promoter methylation of
MIR137HG (particularly in MPM cells with low basal
expression), which is consistent with studies in other
tumor types.20 This supports the notion that methylation
is a frequent cause of miR-137 silencing in MPM and
suggests that a combination of CNV and promoter
methylation leads to the dysregulation of miR-137.
Contrary to our ﬁndings, studies of miR-137 expres-
sion in other tumor types report either a consistent
upregulation or, more commonly, downregulation of
miR-137.19,20,31 Our data show that miR-137 expression
in MPM can be split into three groups: high expressers,
moderate expressers, and low expressers. Additionally,
although high miR-137 expression is commonly associ-
ated with favorable prognosis in other cancers,20,32 here
we have shown that elevated miR-137 was associated
with shorter survival in both series of patients with
MPM. We did not see an effect of inhibiting miR-137 on
target expression or cell growth but, somewhat unex-
pectedly, a miR-137 mimic demonstrated tumor sup-
pressive activity in MPM cells, as evidenced by its ability
to suppress proliferation, colony formation, migration,
and invasion. Similar tumor suppressor effects of miR-
137 have been observed in other cancers,19,20,32 with
the exception of bladder cancer, in which miR-137 acts
as an oncogenic miRNA.31
Interestingly, although miR-137 loss has been impli-
cated in early colorectal carcinogenesis,19 another study
found that elevated miR-137 was linked to shorter sur-
vival in patients with CRC.33 This group also found that
elevating miR-137 induced growth inhibition of CRC cell
lines,33 mirroring our results in MPM cells. It is possible
that, similarly to what occurs in CRC, miR-137 loss is
linked to MPM tumorigenesis and it plays a tumor sup-
pressor role in early MPM. Then, as the tumor
progresses and the biology of the cells change, elevated
miR-137 results in increased aggressiveness, explaining
its association with poor MPM prognosis. A similar
counterintuitive relationship also exists for BAP1, a
frequently mutated tumor suppressor in MPM. Germline
3p21 loss is associated with BAP1 cancer syndrome—an
increased risk for development of certain cancer types
such as mesothelioma.8 Fascinatingly, although these
individuals are more susceptible to MPM development,
BAP1 loss signiﬁcantly increases the median survival of
patients with both familial and sporadic MPM after
diagnosis.34
In this study, transfection of miR-137 mimic down-
regulated CDK6, AKT-2, and YBX1 mRNA levels, and
miR-137 directly inhibited the expression of YBX1
expression. MiR-137–mediated CDK6 suppression is
linked to growth inhibition and G0/G1 cell cycle arrest,20
whereas targeting AKT-2 in gastric cancer is linked to
dampened tumorigenesis.35 Other potentially interesting
targets of miR-137 include cyclooxygenase 2,36 which is
known to be overexpressed in MPM,37 and myeloid cell
leukemia 1,38 which we have shown to be oncogenic in
MPM.27 There was a signiﬁcant negative correlation
between YBX1 protein and miR-137 expression,
implying a biologically relevant role for this interaction
in MPM. When transfected with a combination of miR-
137 mimic and YBX1-speciﬁc siRNA, most cells respon-
ded with reduced growth, whereas all demonstrated
signiﬁcant migration and invasion inhibition to a level
similar as with mimic alone. This strongly implies that
YBX1 is the most important miR-137 target contributing
to migration and invasion in these cells.
YBX1 is an important factor in cancer cell growth, and
its overexpression in tumors correlates with poor pa-
tient survival.39 Studies have shown that miR-137–
mediated YBX1 downregulation leads to reduced
tumorigenic properties of other cancers.40,41 YBX1 and
its positive regulator twist family bHLH transcription
factor 1 are expressed highly in sarcomatoid MPM, and
both are linked to epithelial-mesenchymal transition.42
Here, YBX1 was required for the proliferation of some
Figure 6. Y-box binding protein 1 gene (YBX1) knockdown inhibits malignant pleural mesothelioma (MPM) cell proliferation,
colony formation, invasion, and migration. (A) Growth inhibition assay of MPM cell lines over 96 hours after transfection of
YBX1 siRNA, miR-137 mimic or control (Co) small interfering (siRNA) (Co) at the indicated concentrations. Data are
normalized to Co-transfected cells at 96 hours and expressed as mean plus or minus SE of the mean of the percentage of Co-
transfected cells at 96 hours and representative of three independent experiments performed in triplicate. (B) Represen-
tative pictures and quantiﬁcation of colonies formed in response to YBX1-speciﬁc or Co siRNA transfection at the indicated
concentrations normalized to Co mimic stained with crystal violet. (C) Invasion of cells transfected with 5 nM YBX1-speciﬁc
siRNA or in combination with 5 nM miR-137 mimic in relation to respective Cos in an agar-spot (white line) invasion assay after
48 hour. Scale bar ¼ 250 mm. (D) Cumulative migrated distance (mm) of single cells transfected with miR-137 mimic or YBX1-
speciﬁc or Co siRNAs (5 nM) in 25 hours assessed by videomicroscopy. *p < 0.05, **p < 0.01, ***p < 0.001.
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cell lines and was essential in the colony-forming ability,
migration, and invasion of all MPM cells tested, which is
consistent with its role in the invasion and migration of
other cancer cell types.39 Taken together, our results
show that YBX1 is an important target of miR-137,
particularly as it is so integrally involved in invasion
and migration of MPM, a malignancy characterized by
aggressive local invasion. In addition to miR-137, other
factors may contribute to the regulation of YB1 in MPM.
Besides miR-137, several miRNAs are known to bind and
down-regulate YBX1, such as miR-382.43 In addition to
miRNAs, twist family bHLH transcription factor 1
directly targets and enhances YB1 expression and is
differentially expressed in sarcomatoid versus non-
sarcomatoid MPM.42,44
The application of effective miRNA- and siRNA-based
therapies is becoming feasible thanks to the develop-
ment of novel miRNA deliverymethods, such as EnGeneIC
Dream Vector nanocells (EDVs).45 We have performed
several preclinical studies utilizing EDVs in MPM26,27 and
have completed a phase I clinical trial with intravenously
administered miRNA-loaded EDVs.18 Our functional data
suggest that YB1 knockdown may have therapeutic sig-
niﬁcance. Interestingly, nude mice inoculated with NSCLC
A549 cells transfected with YBX1 siRNA showed impaired
tumor growth compared with siRNA control–transfected
cells.46 Additionally, the ability of EDVs to deliver
siRNAs47 as well as miRNA mimics makes a strong case
for use of YBX1-speciﬁc siRNAs in future in vivo MPM
studies. Additional methods of YBX1 inhibition include
use of a cell-permeable peptide able to inhibit YBX1
Serine 102 phosphorylation through molecular docking,
which reduced YBX1–mediated growth inhibition and
resistance to trastuzumab.48 This may also be applicable
in MPM and warrants further investigation.
In conclusion, our results indicate that miR-137 is
dysregulated in MPM because of CNV and hyper-
methylation of the MIR137HG promoter. Furthermore,
elevating miR-137 levels in cells inhibits the malignant
characteristics of MPM. This activity is explained, at least
in part, by targeting YBX1—an important factor in the
colony formation, migration, and invasion of MPM cells.
By characterizing an important biological interaction
between two regulatory factors involved in the inherent
invasiveness of MPM, our study furthers the under-
standing of MPM biology and provides potential targets
for therapeutic intervention.
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